Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: J07BM02

Cervarix(human papillomavirus1 type 16 L1 protein;human papillomavirus type 18 L1 protein)

Papillomavirus Infections;Uterine Cervical Dysplasia;Immunization

Marketing Authorisation Holder: GlaxoSmithKline Biologicals S.A.

EMA Authorisation: 20/09/2007

INN: human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed)

Indication

Cervarix is a vaccine for use from the age of 9 years for the prevention of premalignant ano-genital lesions (cervical, vulvar, vaginal and anal) and cervical and anal cancers causally related to certain oncogenic Human Papillomavirus (HPV) types. See sections 4.4 and 5.1 for important information on the data that support this indication. The use of Cervarix should be in accordance with official recommendations.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Cervarix — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.